NIGMS

Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping

Retrieved on: 
Thursday, March 21, 2024
Single-cell analysis, Stem cell, Growth, Cell, WUSTL, Associate, Partnership, Microfluidics, SBIR, Fluency, NIGMS, Genomics, CRISPR, CSO, Fine chemical

This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.

Key Points: 
  • This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
  • Ultima Genomics sequencing of the prototype million-cell PIPseq data revealed clonal lineage trees with restriction of specific cell reprogramming fates.
  • "The collaboration between Fluent BioSciences and Ultima represents a remarkable synergy in pushing the boundaries of single-cell analysis," said Brian McKernan, CEO of Fluent BioSciences.
  • To learn more about Fluent BioSciences' million-cell PIPseq prototype kits and how they can empower high-throughput single-cell profiling, please contact [email protected] .

Assistant Professor of Biology Awarded Nearly $1.8 Million Research Award by the National Institutes of Health

Retrieved on: 
Tuesday, September 26, 2023
Tissue, Human, Clarkson University, Hunting, National Institute of General Medical Sciences, Research, Mentorship, Cell, Fruit, Bangladesh Technical Education Board, Student, MIRA, Disease, Pharmaceutical industry, Management, NIGMS, Biology

Potsdam, NY, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ginger Hunter, an assistant professor of Biology at Clarkson University, has been awarded a Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health.

Key Points: 
  • Potsdam, NY, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ginger Hunter, an assistant professor of Biology at Clarkson University, has been awarded a Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health.
  • The nearly $1.8 million grant began August 2023 and will last for five years.
  • Cells in these tissues usually start off unorganized, but during development become organized due to cell-cell communication events across large and small distances.
  • Defects in cell-cell communication during patterning can lead to human disorders and disease.

Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients

Retrieved on: 
Monday, September 11, 2023
Sepsis, SBIR, National Institute of General Medical Sciences, Bangladesh Technical Education Board, Fluid, Small Business Innovation Research, Death, Patient, Blood volume, NIGMS, NIH, Pharmaceutical industry, Medical imaging

Oak Ridge, TN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) has awarded the Company a $305K Phase I Small Business Innovative Research (SBIR) grant to support the development of the Sepsis FLO (Sepsis Fluid Optimizer), a clinical decision support tool designed to precisely guide blood volume management and treatment in sepsis patients.

Key Points: 
  • Oak Ridge, TN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) has awarded the Company a $305K Phase I Small Business Innovative Research (SBIR) grant to support the development of the Sepsis FLO (Sepsis Fluid Optimizer), a clinical decision support tool designed to precisely guide blood volume management and treatment in sepsis patients.
  • “Sepsis impacts 1.7 million Americans annually, leading to 270,000 deaths and $62 billion in costs,” said Michael Feldschuh, CEO and President of Daxor Corporation.
  • “There is a significant unmet need for a rapid bedside test with a clinically validated sepsis fluid guidance support tool based on precise, objective assessment of circulating blood volume.
  • “The development of a clinical decision-support system will help clinicians translate blood volume analysis results into actionable treatment decisions.”

NIH Awards Prenosis With Two Grants Totaling $4.8 million to Enable Precision Medicine for Sepsis

Retrieved on: 
Wednesday, July 12, 2023
Infection, Partnership, Society, Housing, Biomedical Advanced Research and Development Authority, Sepsis, Society of Critical Care Medicine, EMR, SBIR, TED (conference), National Institute of General Medical Sciences, Research, Electronic health record, Biomarker, American Thoracic Society, Development, Death, Hospital, Collection, Patient, Data, Machine learning, Algorithm, Medicine, Artificial intelligence, Biosafety, Biology, Mortality, American Association for Clinical Chemistry, WHO, NIGMS, BARDA, Medtech, NIH, MDDI, National Institutes of Health Clinical Center, Critical Care Medicine (journal), Pharmaceutical industry, Medical imaging, Nursing

CHICAGO, July 12, 2023 /PRNewswire/ -- Prenosis, Inc., an artificial intelligence company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH). The grants will study the use of Prenosis's Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime. The goal is to better understand how patients' health states rapidly evolve in acute care environments.

Key Points: 
  • Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime.
  • The goal is to better understand how patients' health states rapidly evolve in acute care environments.
  • The outcomes of these studies could usher in a new era of predictive diagnostics, clinical decision support tools, improved clinical trials, and precision medicine drugs for sepsis.
  • Prenosis generates deep biological profiles of each patient by measuring critical sepsis biomarkers in its Biological Safety Level 2 lab in Chicago.

Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

Retrieved on: 
Tuesday, August 2, 2022
National, Algorithm, NIH, RNA splicing, Research associate, Genome, Small Business Innovation Research, Neurodegeneration, Research, SBIR, IO, National Institute, Artificial intelligence, National Institute of General Medical Sciences, Risk, National Cancer Institute, Robert H. Lurie Comprehensive Cancer Center, Machine learning, Biotechnology, Disease, Cold, Patient, Breast cancer, NIGMS, Therapy, Feinberg School of Medicine, RNA-Seq, Breast, Lists of diseases, Cold Spring Harbor Laboratory, RNA, NCI, Pharmaceutical industry, Vaccine, Cancer

This grant will provide $2 million over 2 years to commercialize Envisagenics' proprietary drug discovery platform, SpliceIOTM, for the discovery of novel targets for immuno-oncology (IO) therapeutic development.

Key Points: 
  • This grant will provide $2 million over 2 years to commercialize Envisagenics' proprietary drug discovery platform, SpliceIOTM, for the discovery of novel targets for immuno-oncology (IO) therapeutic development.
  • Envisagenics was previously awarded Phase I and Phase II grants from the National Institute of General Medical Sciences (NIGMS, NIH) to develop the SpliceCore software platform.
  • A Phase I SBIR grant was also awarded by the NCI to expand SpliceCore's capabilities for discovery of splicing-derived neoantigens.
  • Envisagenics is a spin-out of Cold Spring Harbor Laboratory and a proud woman- and minority-led recipient of several grants from the National Institute of General Medical Sciences and the National Cancer Institute.

CHOP Researchers Develop New Computational Tool to Interpret Clinical Significance of Cancer Mutations

Retrieved on: 
Friday, May 6, 2022
ASCO, Decision-making, Mutation, NLM, National, AMP, Somatic mutation, Deep learning, Health, CHOP, NIH, Wang, College, NGS, Patient, Prussia, Doctor of Philosophy, National Institute of General Medical Sciences, Association, Clinical trial, American Society of Clinical Oncology, Neoplasm, Philadelphia, NIGMS, Cancer, Pathology, Knowledge, Diagnosis, Hospital, Medical laboratory, Children's Hospital of Philadelphia, Machine learning, MD, DOI, Publication, CAP, Science Advances, Precision medicine, Prognosis, Classification, Disease, NHGRI, Science Publishing Group, Research, Growth, Medical imaging, Medical device, Child

PHILADELPHIA, May 6, 2022 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have developed a new tool to help researchers interpret the clinical significance of somatic mutations in cancer. The tool, known as CancerVar, incorporates machine learning frameworks to go beyond merely identifying somatic cancer mutations and interpret the potential significance of those mutations in terms of cancer diagnosis, prognosis, and targetability. A paper describing CancerVar was published today in Science Advances.

Key Points: 
  • PHILADELPHIA, May 6, 2022 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have developed a new tool to help researchers interpret the clinical significance of somatic mutations in cancer.
  • The tool, known as CancerVar , incorporates machine learning frameworks to go beyond merely identifying somatic cancer mutations and interpret the potential significance of those mutations in terms of cancer diagnosis, prognosis, and targetability.
  • "CancerVar documents and harmonizes various types of clinical evidence including drug information, publications, and pathways for somatic mutations in detail.
  • In addition to including millions of somatic mutations, whether of known significance or not, the tool uses deep learning to improve clinical interpretation of those mutations.

iECURE Appoints George Diaz, M.D., Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders

Retrieved on: 
Monday, April 25, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Medical genetics, Cornell University, Lists of diseases, Icahn School of Medicine at Mount Sinai, Pediatrics, GTP, Degenerative disease, Genetics, VP, Research, Gene expression, State university system, Congenital disorders of amino acid metabolism, RNA, Program, OTC, UCD School of Medicine, Patient, Gene editing, LinkedIn, James Wilson, Inborn errors of metabolism, Institute of Liver and Biliary Sciences, American, Liver, Metabolism, Human Genome Sciences, National Institute of General Medical Sciences, UCD, Nerve, Division, National Institute, Biology, Industry, Mutation, Coma, NIGMS, University, Therapy, Pharmaceutical industry, Medicine

Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders (UCDs).

Key Points: 
  • Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders (UCDs).
  • George is a key hire as we solidify the clinical strategies for our gene editing programs.
  • Patient communities in UCDs need durable treatment options and Georges guidance will be integral as iECURE embarks on clinical development and beyond.
  • Dr. Diaz has more than 25 years of experience in genetics and pediatrics, particularly in metabolic diseases and monogenic disorders.

NIH Backs Kinetic River Approach to Autofluorescence-Free Flow Cytometry with Phase II SBIR Grant

Retrieved on: 
Wednesday, March 23, 2022
Cell, NIGMS, National, Arno, Talon, Biomarker, Research, National Institute, SBIR, Infection, Biology, NIH, Acute myeloid leukemia, Technology, Biomedical Research, Mount Sinai, Icahn School of Medicine at Mount Sinai, Cell biology, Engineering, Solution, Flow cytometry, Fluorescence, Lymphatic system, National Institute of General Medical Sciences, Patient, Disease, Phase, Pharmaceutical industry, Microscope

MOUNTAIN VIEW, Calif., March 23, 2022 /PRNewswire/ -- Kinetic River Corp., a leader in advanced flow cytometry technologies, announced today it has been awarded a Phase II Small Business Innovation Research (SBIR) grant funded by the U.S. National Institutes of Health (NIH). The competitive $2.5-M grant was awarded by the National Institute of General Medical Sciences (NIGMS), which fosters development of innovative biomedical platforms. This is the fifth SBIR award received by Kinetic River to date and supports the company's industry-leading development of an autofluorescence-free flow cytometry platform for enhanced analytical sensitivity.

Key Points: 
  • This is the fifth SBIR award received by Kinetic River to date and supports the company's industry-leading development of an autofluorescence-free flow cytometry platform for enhanced analytical sensitivity.
  • The time-resolved cell analysis technology developed at Kinetic River has applications beyond automated autofluorescence removal, including compensation-free flow cytometry (the subject of another NIH-funded Phase II SBIR project recently completed by Kinetic River) and highly multiparametric flow cytometry.
  • About Kinetic River - Kinetic River Corp. designs and manufactures advanced flow cytometry systems.
  • Kinetic River and the Kinetic River logo are registered trademarks of Kinetic River Corp.
    Research reported in this release was supported by NIGMS of the National Institutes of Health under grant numbers R43GM131619 and R44GM131619.

Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.

Retrieved on: 
Monday, October 4, 2021
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Patent, Infection, Hand, Vaccine, National, FDA, Mutacin 1140, U.S. Securities and Exchange Commission, Acinetobacter baumannii, Engineering, Enterococcus, Immunization, Food chain, Private Securities Litigation Reform Act, National Research Council, Communication, Enterococcus faecium, Agriculture, Pseudomonas aeruginosa, Florida International University, Staphylococcus aureus, Small business, Enterobacter, COVID-19, Klebsiella pneumoniae, Research, NIGMS, ESKAPE, NIH, Terra, FIU, NYSE, Pharmaceutical industry

The grant provides Oragenics with funding to develop novel lantibiotics for the treatment of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.).

Key Points: 
  • The grant provides Oragenics with funding to develop novel lantibiotics for the treatment of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.).
  • Telling added, We believe that lantibiotics represent a large untapped pipeline for the development of novel antibiotics.
  • Mutacin 1140 is a lantibiotic discovered by Oragenics, that has provided a basis for the Companys antibiotic research and development and engineering.
  • This funding will support additional molecular modeling efforts and other activities, including in collaboration with FIU, to develop new lantibiotic compounds.

Kinetic River Corp. Receives First Japanese Patent for Time-Resolved Flow Cytometry

Retrieved on: 
Friday, October 1, 2021
Patent, Biomedical Research, Research, National, Solution, Cancer, Flow cytometry, Microparticle, Immunophenotyping, Silicon, Technology, NIGMS, Color, Cell, Intellectual property, Fluorescence, AIDS, Television, Medical imaging

MOUNTAIN VIEW, Calif., Oct. 1, 2021 /PRNewswire/ --Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies for time-resolved flow cytometry.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 1, 2021 /PRNewswire/ --Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies for time-resolved flow cytometry.
  • "We are very excited about the Japanese Patent Office's decision," said Giacomo Vacca, Ph.D., president of Kinetic River.
  • By establishing patent protection for this technology suite in Japan, this patent allows Kinetic River to pursue a sizable, growing market with presence across all the major flow cytometry segments.
  • Kinetic River and the Kinetic River logo are registered trademarks of Kinetic River Corp.